Hematologia
Revisão | Linfo-histiocitose hemofagocítica em pacientes com HIV.
12 Mai, 2022 | 14:53hA Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases
Ponto/Contraponto | Heparina terapêutica deveria ser administrada para pacientes críticos internados com COVID-19?
4 Mai, 2022 | 14:00hCONTRPONTO: Should Therapeutic Heparin Be Administered to Acutely Ill Hospitalized Patients With COVID-19? No – CHEST
Ver também: Rebuttal From Dr Tritschler et al – CHEST
Conteúdos relacionados:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
5 principais desafios da gestão de antibióticos em doenças infecciosas relacionadas a transplante e estratégias práticas para abordá-las.
2 Mai, 2022 | 13:55h
Comentário no Twitter
🆕💥Review Article @ASHE_Journal
Bring it on: Top five antimicrobial stewardship challenges in transplant infectious diseases and practical strategies to address them #IDTwitter #medtwitter #TwitteRx #MedEd https://t.co/ToPLQXtC4r pic.twitter.com/pZQWWb3ZSx— Antibiotic Steward Bassam Ghanem🆔🔥 (@ABsteward) April 28, 2022
Sob licença de http://creativecommons.org/licenses/by/4.0/
Diretriz | Linfomas cutâneos.
27 Abr, 2022 | 15:32hRevisão | Novos tratamentos para linfomas não Hodgkin de células B.
25 Abr, 2022 | 12:36hNovel treatments in B cell non-Hodgkin’s lymphomas – The BMJ
Comentário no Twitter
READ: new State of the Art review on novel treatments in B cell non-Hodgkin’s lymphomas.
Learn about mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in treatment https://t.co/EIri6jDBcv
— The BMJ (@bmj_latest) April 22, 2022
Diretriz britânica para tratamento da leucemia linfocítica crônica.
25 Abr, 2022 | 12:22hGuideline for the treatment of chronic lymphocytic leukaemia – British Journal of Haematology
Estudo randomizado | Ivosidenibe e azacitidina na leucemia mieloide aguda IDH1-mutante.
25 Abr, 2022 | 12:20hIvosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Ivosidenib and azacitidine showed clinical benefit as compared with placebo and azacitidine in patients with newly diagnosed IDH1-mutated AML, a difficult-to-treat population. https://t.co/6K6mWJdd2V pic.twitter.com/qOwOvHcV4j
— NEJM (@NEJM) April 20, 2022
Estimativas nacionais, regionais e globais de anemia conforme a gravidade em mulheres e crianças de 2000 a 2019.
21 Abr, 2022 | 12:09hComentário convidado: Sustainable Development Goals for anaemia: 20 years later, where are we now? – The Lancet Global Health
Índice de estresse e ativação endotelial (EASIX – endothelial activation and stress index) pré-transplante pode predizer danos causados por sepse após transplante alogênico de células-tronco.
21 Abr, 2022 | 11:30hPre-transplant EASIX and sepsis after allogeneic stem cell transplantation – Intensive Care Medicine
Comentário no Twitter
🧪 Endothelial complications major causes of mortality post alloSCT. Pre Tx Endothelial Activation & Stress IndeX EASIX (basic lab data characterizing Tx-associated thrombotic microangiopathy) powerful marker of #sepsis, dysfunctional endothelial response.https://t.co/FRGUGT8L78 pic.twitter.com/VF2wTLCHaM
— Intensive Care Medicine (@yourICM) April 18, 2022
Estudo clínico fases 1-2 | Rilzabrutinibe, um inibidor BTK oral, na trombocitopenia imune.
21 Abr, 2022 | 11:21hRilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: Rilzabrutinib for blood disorder shows promise in phase 1–2 clinical trial – Massachusetts General Hospital
Comentário no Twitter
Rilzabrutinib had rapid and durable clinical activity in adults with immune thrombocytopenia, with low-level toxic effects. https://t.co/boWT4LpQkk pic.twitter.com/ZpNXHYL2Gv
— NEJM (@NEJM) April 18, 2022